Financial reports
Current reports
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
5 Apr 24
6-K
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
4 Apr 24
6-K
Current report (foreign)
29 Feb 24
6-K
GENFIT Announces 2024 Financial Calendar
17 Jan 24
6-K
Current report (foreign)
11 Jan 24
6-K
Current report (foreign)
8 Dec 23
6-K
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
7 Dec 23
6-K
Current report (foreign)
6 Dec 23
Registration and prospectus
F-3
Shelf registration (foreign)
18 Apr 23
S-8
Registration of securities for employees
18 Apr 23
424B4
Prospectus supplement with pricing info
27 Mar 19
F-1MEF
Registration statement to add securities to prior F-1 registration
26 Mar 19
8-A12B
Registration of securities on exchange
22 Mar 19
F-1/A
Registration statement (foreign) (amended)
14 Mar 19
F-1
Registration statement (foreign)
27 Feb 19
DRS/A
Draft registration statement (amended)
15 Feb 19
DRSLTR
Correspondence regarding draft registration statement
15 Feb 19
DRS/A
Draft registration statement (amended)
11 Feb 19
Proxies
No filings
Other
EFFECT
Notice of effectiveness
5 May 23
CORRESP
Correspondence with SEC
2 May 23
UPLOAD
Letter from SEC
25 Apr 23
EFFECT
Notice of effectiveness
27 Mar 19
CERT
Certification of approval for exchange listing
25 Mar 19
CORRESP
Correspondence with SEC
22 Mar 19
CORRESP
Correspondence with SEC
22 Mar 19
CORRESP
Correspondence with SEC
13 Mar 19
CORRESP
Correspondence with SEC
27 Feb 19
UPLOAD
Letter from SEC
19 Feb 19